Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11775651 | 0.91 | RRM1 (0.49) | DPP7RRM1DNM1TSHRALDH1A1 | |
| SCHEMBL8166834 | 0.91 | RRM1 (0.49) | DPP7RRM1DNM1TSHRALDH1A1 | |
| SCHEMBL11774595 | 0.88 | DNM1 (0.40) | DPP7RRM1DNM1TSHRALDH1A1 | |
| SCHEMBL11776112 | 0.85 | DPP7 (0.34) | DPP7RRM1CA1 | |
| SCHEMBL6658508 | 0.84 | DNM1 (0.40) | DPP7DNM1TSHRALDH1A1MEN1 | |
| SCHEMBL1721427 | 0.82 | DNM1 (0.44) | DPP7DNM1TSHRALDH1A1MEN1 | |
| SCHEMBL12056180 | 0.81 | ALDH1A1 (0.39) | DPP7RRM1DNM1TSHRALDH1A1 | |
| SCHEMBL1885258 | 0.81 | DNM1 (0.36) | DNM1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6658739 | 0.81 | ALDH1A1 (0.39) | DPP7RRM1DNM1TSHRALDH1A1 | |
| SCHEMBL11772104 | 0.80 | DNM1 (0.48) | DPP7RRM1DNM1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461120-B2 | Macrocyclic compounds pounds and methods of use thereof | SYNOVO GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-20110183237-A1 | ANION CONDUCTING ELECTROLYTE RESIN AND A METHOD FOR PRODUCING THE SAME | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110028417-A1 | Macrocyclic Compounds and Methods of Use Thereof | SYNOVO GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-7767797-B1 | Macrocyclic compounds and methods of use thereof | SYNOVO GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| US-6677452-B1 | PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE | LION BIOSCIENCE AG (DE) | 2004-01-13 | — | — | US | disclosed |
| EP-0187371-B1 | SUBSTITUTED ISOQUINOLINESULFONYL COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-06-19 | — | — | EP | disclosed |
| US-4678783-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES, ARTERIOSCLEROSIS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0187371-A2 | Substituted isoquinolinesulfonyl compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028417-A1 | Macrocyclic Compounds and Methods of Use Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PCSK9, CYP11B2 | DPP7 165/4885RRM1 2138/4885DNM1 770/4885 |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | DPP7 571/4885RRM1 3985/4885DNM1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.